Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2856 +0.0006 (+0.21%)
Official Closing Price Updated: 8:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
Via ACCESS Newswire
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
Via ACCESS Newswire
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
Via ACCESS Newswire
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Via ACCESS Newswire
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
Via ACCESS Newswire
IGC Pharma Reports Third Quarter Fiscal 2025 Results
Via ACCESS Newswire
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
Via ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Via ACCESS Newswire
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
Via ACCESS Newswire
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
Via ACCESS Newswire
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
Via ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
Via ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Via ACCESSWIRE
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Via ACCESSWIRE
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
Via ACCESSWIRE
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Via ACCESSWIRE
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
Via ACCESSWIRE
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Via ACCESSWIRE
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge),... 
Via PRLog
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence Intellectual Property Legal
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Via ACCESSWIRE
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
Via ACCESSWIRE
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence Intellectual Property Legal
IGC Announces Results of its 2024 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback